ReviewExpert review of vaccines2019
Progress towards the development of Klebsiella vaccines.
Review in Expert review of vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Pooled it
- A universally conserved OMV-YidR conjugate nanovaccine confers broad protection against hypervirulent and carbapenem-resistantEmerging microbes & infections · 2026Article
- Pre-Clinical Development of Two DNA Vaccines Encoding MrkA of Klebsiella pneumoniae: Effect of Plasmid Backbone on Immunogenicity and Protective Efficacy Against Sepsis.Microbial biotechnology · 2026Article
- High-throughput antigen discovery using Functional Genomic Vaccinology (FGV) identifies protective Streptococcus pneumoniae vaccine candidates.Nature communications · 2026Article
- GMMA as delivery system for Klebsiella pneumoniae O-antigens and K-antigens.Scientific reports · 2026Article
- Understanding the impact of Klebsiella pneumoniae K-Antigen based MAPS vaccine design on the immune response in animal models.PLoS pathogens · 2026Article
- Modular Development of aNanomaterials (Basel, Switzerland) · 2026Article
- Klebsiella vaccine research and development in Africa: a rapid scoping review of current evidence and future priorities.BMJ public health · 2026Article
- Variable progressive behavior ofFrontiers in immunology · 2026Article
- Article
- Modular assembly and immunological evaluation of a promising bioconjugate nanovaccine against Klebsiella pneumoniae O2 serotype.NPJ vaccines · 2025Article
- Evaluation of capsule polysaccharide (CPS)-specific antibodies for broad recognition of prominent multidrug-resistantMicrobiology spectrum · 2025Article
- O-antigen polysaccharides inMicrobiology and molecular biology reviews : MMBR · 2025Review
- The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design.Communications biology · 2025Article
- Development and Characterization of a Ten-Plex Assay to MeasureMethods and protocols · 2025Article
- Antibody responses in Klebsiella pneumoniae bloodstream infection: a prospective cohort study.The Lancet. Microbe · 2025Article
- Insights into the roles of macrophages in Klebsiella pneumoniae infections: a comprehensive review.Cellular & molecular biology letters · 2025Review
- mRNA-LNP vaccines combined with tPA signal sequence elicit strong protective immunity againstmSphere · 2025Article
- TheVaccines · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.